{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:27:49Z","timestamp":1791336469942,"version":"4.3.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,1,21]],"date-time":"2013-01-21T00:00:00Z","timestamp":1358726400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"},{"start":{"date-parts":[[2013,1,21]],"date-time":"2013-01-21T00:00:00Z","timestamp":1358726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/2.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Memantine and cholinesterase inhibitors potentially offer additional benefits in Alzheimer's disease (AD) when used together. This study assessed the efficacy and safety of combination treatment with memantine added to stable donepezil in patients with moderate to severe AD, and in a subset with moderate AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Post hoc meta-analyses of data combined from two 24-week, randomised, double-blind, placebo-controlled trials of memantine 20 mg\/day versus placebo, added to a stable cholinesterase inhibitor, were conducted. Data were included for all patients receiving donepezil 10 mg\/day with Mini-Mental State Examination (MMSE) scores &lt; 20 (\n                      <jats:italic>n<\/jats:italic>\n                      = 510). Efficacy was assessed using measures of cognition, function, and global status. Furthermore, marked clinical worsening, defined as concurrent deterioration from baseline in the three main efficacy domains, and safety, measured by treatment-emergent adverse events, were assessed. Analyses were performed for patients with moderate to severe AD (MMSE 5-19; MOD-SEV subgroup), and also for patients with moderate AD (MMSE 10-19; MOD subgroup;\n                      <jats:italic>n<\/jats:italic>\n                      = 367).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At week 24, in the MOD-SEV subgroup, patients receiving memantine added to donepezil significantly outperformed those receiving placebo added to donepezil in measures of cognition (\n                      <jats:italic>P<\/jats:italic>\n                      &lt; 0.0001), function (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.02), and global status (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.010), with standardised mean differences (SMDs) of 0.36, 0.21, and 0.23, respectively (all last observation carried forward). Similarly, in the MOD subgroup, significant benefits were observed for cognition (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.008), function (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.04) and global status (\n                      <jats:italic>P<\/jats:italic>\n                      = 0.008), with SMDs of 0.28, 0.21, and 0.28, respectively. Significantly fewer patients receiving memantine added to donepezil showed marked clinical worsening than those receiving placebo added to donepezil, in both subgroups (MOD-SEV: 8.7% versus 20.4%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.0002; MOD: 5.9% versus 15.0%,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006). The incidence of adverse events was similar between treatment groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results support and extend previous evidence that combination treatment with memantine added to stable donepezil in patients with moderate AD, and in those with moderate to severe AD, is associated with significant benefits in reducing 24-week decline in cognition, function and global status. Combination treatment produces substantially reduced rates of marked clinical worsening, has good safety and tolerability, and generates effect sizes that are both statistically significant and clinically meaningful.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/alzrt160","type":"journal-article","created":{"date-parts":[[2013,1,21]],"date-time":"2013-01-21T10:14:15Z","timestamp":1358763255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy"],"prefix":"10.1186","volume":"5","author":[{"given":"Alireza","family":"Atri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 L","family":"Molinuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Lemming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Wirth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Pulte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,1,21]]},"reference":[{"key":"134_CR1","first-page":"417","volume":"10","author":"DS Geldmacher","year":"2006","unstructured":"Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, Banerjee S, Lin P, Sano M: Realistic expectations for treatment success in Alzheimer's disease. J Nutr Health Aging. 2006, 10: 417-429.","journal-title":"J Nutr Health Aging"},{"key":"134_CR2","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2006.07.001","volume":"2","author":"JL Cummings","year":"2006","unstructured":"Cummings JL: Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement. 2006, 2: 263-271. 10.1016\/j.jalz.2006.07.001.","journal-title":"Alzheimers Dement"},{"key":"134_CR3","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein MF, Folstein SE, McHugh PR: \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiat Res. 1975, 12: 189-198. 10.1016\/0022-3956(75)90026-6.","journal-title":"J Psychiat Res"},{"key":"134_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0","volume":"14","author":"B Winblad","year":"1999","unstructured":"Winblad B, Poritis N: Memantine in severe dementia: results of the M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry. 1999, 14: 135-146. 10.1002\/(SICI)1099-1166(199902)14:2<135::AID-GPS906>3.0.CO;2-0.","journal-title":"Int J Geriatr Psychiatry"},{"key":"134_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","volume":"348","author":"B Reisberg","year":"2003","unstructured":"Reisberg B, Doody R, St\u00f6ffler A, Schmitt F, Ferris S, M\u00f6bius HJ, Memantine Study Group: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003, 348: 1333-1341. 10.1056\/NEJMoa013128.","journal-title":"N Engl J Med"},{"key":"134_CR6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1159\/000105162","volume":"24","author":"D Wilkinson","year":"2007","unstructured":"Wilkinson D, Andersen HF: Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease. Dement Geriatr Cogn Disord. 2007, 24: 138-145. 10.1159\/000105162.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"134_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1212\/WNL.50.1.136","volume":"50","author":"SL Rogers","year":"1998","unstructured":"Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT: A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group. Neurology. 1998, 50: 136-145. 10.1212\/WNL.50.1.136.","journal-title":"Neurology"},{"key":"134_CR8","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1212\/WNL.57.4.613","volume":"57","author":"H Feldman","year":"2001","unstructured":"Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Donepezil MSAD Study Investigators Group: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology. 2001, 57: 613-620. 10.1212\/WNL.57.4.613.","journal-title":"Neurology"},{"key":"134_CR9","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1212\/WNL.57.3.489","volume":"57","author":"B Winblad","year":"2001","unstructured":"Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, Wetterholm AL, Zhang R, Haglund A, Subbiah P, Donepezil Nordic Study Group: A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001, 57: 489-495. 10.1212\/WNL.57.3.489.","journal-title":"Neurology"},{"key":"134_CR10","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1185\/03007990903236731","volume":"25","author":"B Winblad","year":"2009","unstructured":"Winblad B, Black SE, Homma A, Schwam EM, Moline M, Xu Y, Perdomo CA, Swartz J, Albert K: Donepezil treatment in severe Alzheimer's disease: a pooled analysis of three clinical trials. Curr Med Res Opin. 2009, 25: 2577-2587.","journal-title":"Curr Med Res Opin"},{"key":"134_CR11","volume-title":"Cochrane Database Syst Rev","author":"J Birks","year":"2006","unstructured":"Birks J, Harvey RJ: Donepezil for dementia due to Alzheimer's disease. Cochrane Database Syst Rev. 2006, CD001190"},{"key":"134_CR12","volume-title":"Cochrane Database Syst Rev","author":"R McShane","year":"2006","unstructured":"McShane R, Areosa Sastre A, Minakaran N: Memantine for dementia. Cochrane Database Syst Rev. 2006, CD003154"},{"key":"134_CR13","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1159\/000241877","volume":"28","author":"D Wilkinson","year":"2009","unstructured":"Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones RW, Gauthier S, Lopez OL, Cummings J, Xu Y, Feldman HH: Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer's disease. Dement Geriatr Cogn Disord. 2009, 28: 244-251. 10.1159\/000241877.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"134_CR14","volume-title":"Alzheimers Dement","author":"S Gauthier","year":"2012","unstructured":"Gauthier S, Molinuevo JL: Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement. 2012, published online 27 October 2012, doi:10.1016\/j.jalz.2011.11.005"},{"key":"134_CR15","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1345\/aph.1D638","volume":"38","author":"AP Periclou","year":"2004","unstructured":"Periclou AP, Ventura D, Sherman T, Rao N, Abramowitz WT: Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother. 2004, 38: 1389-1394. 10.1345\/aph.1D638.","journal-title":"Ann Pharmacother"},{"key":"134_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, Memantine Study Group: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004, 291: 317-324. 10.1001\/jama.291.3.317.","journal-title":"JAMA"},{"key":"134_CR17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/156720508783884576","volume":"5","author":"AP Porsteinsson","year":"2008","unstructured":"Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT, Memantine MEM-MD-12 Study Group: Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008, 5: 83-89. 10.2174\/156720508783884576.","journal-title":"Curr Alzheimer Res"},{"key":"134_CR18","volume-title":"The Severe Impairment Battery","author":"J Saxton","year":"1993","unstructured":"Saxton J, McGonigle KL, Swihart AA, Boller F: The Severe Impairment Battery. 1993, Bury St Edmunds: Thames Valley Test Company"},{"key":"134_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1001\/archneur.1994.00540130067012","volume":"51","author":"M Panisset","year":"1994","unstructured":"Panisset M, Roudier M, Saxton J, Boller F: Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994, 51: 41-45. 10.1001\/archneur.1994.00540130067012.","journal-title":"Arch Neurol"},{"issue":"Suppl 2","key":"134_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/00002093-199700112-00008","volume":"11","author":"FA Schmitt","year":"1997","unstructured":"Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, Ferris SH, Mackell JA, Schafer K, Thal LJ: The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997, 11 (Suppl 2): 51-56.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"134_CR21","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","volume":"141","author":"WG Rosen","year":"1984","unstructured":"Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984, 141: 1356-1364.","journal-title":"Am J Psychiatry"},{"issue":"Suppl 2","key":"134_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1097\/00002093-199700112-00005","volume":"11","author":"D Galasko","year":"1997","unstructured":"Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997, 11 (Suppl 2): 33-39.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"134_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1017\/S1355617705050502","volume":"11","author":"D Galasko","year":"2005","unstructured":"Galasko D, Schmitt F, Thomas R, Jin S, Bennett D, Alzheimer's Disease Cooperative Study: Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc. 2005, 11: 446-453.","journal-title":"J Int Neuropsychol Soc"},{"issue":"Suppl 3","key":"134_CR24","first-page":"8","volume":"11","author":"B Reisberg","year":"1997","unstructured":"Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, Kumar R, Lucca U, Mangone CA, Mohr E, Morris JC, Rogers S, Sawada T: Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. Alzheimer Dis Assoc Disord. 1997, 11 (Suppl 3): 8-18.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"Suppl 2","key":"134_CR25","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/00002093-199700112-00004","volume":"11","author":"LS Schneider","year":"1997","unstructured":"Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH: Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997, 11 (Suppl 2): 22-32.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"134_CR26","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"J Cohen","year":"1988","unstructured":"Cohen J: Statistical Power Analysis for the Behavioral Sciences. 1988, New York, NY: Psychology Press, Taylor & Francis Group, Second","edition":"Second"},{"key":"134_CR27","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1136\/jnnp.2003.029074","volume":"75","author":"K Rockwood","year":"2004","unstructured":"Rockwood K: Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2004, 75: 677-685. 10.1136\/jnnp.2003.029074.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"134_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/01.wad.0000213860.35355.d4","volume":"20","author":"FA Schmitt","year":"2006","unstructured":"Schmitt FA, van Dyck CH, Wichems CH, Olin JT, Memantine MEM-MD-02 Study Group: Cognitive response to memantine in moderate to severe Alzheimer disease patients already receiving donepezil: an exploratory reanalysis. Alzheimer Dis Assoc Disord. 2006, 20: 255-262. 10.1097\/01.wad.0000213860.35355.d4.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"134_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/01.wad.0000213859.35355.59","volume":"20","author":"HH Feldman","year":"2006","unstructured":"Feldman HH, Schmitt FA, Olin JT: Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment. Alzheimer Dis Assoc Disord. 2006, 20: 263-268. 10.1097\/01.wad.0000213859.35355.59.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"134_CR30","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000102568","volume":"24","author":"B Winblad","year":"2007","unstructured":"Winblad B, Jones RW, Wirth Y, St\u00f6ffler A, M\u00f6bius HJ: Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord. 2007, 24: 20-27. 10.1159\/000102568.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"134_CR31","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jalz.2006.10.004","volume":"3","author":"RS Doody","year":"2007","unstructured":"Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM: Meta-analysis of six-month memantine trials in Alzheimer's disease. Alzheimers Dement. 2007, 3: 7-17. 10.1016\/j.jalz.2006.10.004.","journal-title":"Alzheimers Dement"},{"key":"134_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/WAD.0b013e31816653bc","volume":"22","author":"A Atri","year":"2008","unstructured":"Atri A, Shaughnessy LW, Locascio JJ, Growdon JH: Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008, 22: 209-221. 10.1097\/WAD.0b013e31816653bc.","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"134_CR33","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","volume":"80","author":"OL Lopez","year":"2009","unstructured":"Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, Klunk W, Dekosky ST: Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009, 80: 600-607. 10.1136\/jnnp.2008.158964.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"134_CR34","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1159\/000335156","volume":"10","author":"A Atri","year":"2012","unstructured":"Atri A, Rountree SD, Lopez OL, Doody RS: Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. Neurodegener Dis. 2012, 10: 170-174. 10.1159\/000335156.","journal-title":"Neurodegener Dis"},{"key":"134_CR35","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, et al: Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med. 2012, 366: 893-903. 10.1056\/NEJMoa1106668.","journal-title":"N Engl J Med"},{"key":"134_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/01.NT.0000414612.08062.70","volume":"12","author":"G Shaw","year":"2012","unstructured":"Shaw G: Two drugs are not better than one for treating moderate to severe Alzheimer disease, British investigators report: why some US neurologists don't agree. Neurology Today. 2012, 12: 12-13.","journal-title":"Neurology Today"},{"key":"134_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/alzrt7","volume":"1","author":"SD Rountree","year":"2009","unstructured":"Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS: Persistent treatment with cholinesterase inhibitors and\/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009, 1: 7-10.1186\/alzrt7.","journal-title":"Alzheimers Res Ther"},{"key":"134_CR38","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jalz.2011.02.009","volume":"7","author":"S Gillette-Guyonnet","year":"2011","unstructured":"Gillette-Guyonnet S, Andrieu S, Nourhashemi F, Gardette V, Coley N, Cantet C, Gauthier S, Ousset PJ, Vellas B, REAL.FR study group: Long-term progression of Alzheimer's disease in patients under antidementia drugs. Alzheimers Dement. 2011, 7: 579-592. 10.1016\/j.jalz.2011.02.009.","journal-title":"Alzheimers Dement"},{"key":"134_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.4088\/JCP.v69n0302","volume":"69","author":"GK Wilcock","year":"2008","unstructured":"Wilcock GK, Ballard CG, Cooper JA, Loft H: Memantine for agitation\/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008, 69: 341-348. 10.4088\/JCP.v69n0302.","journal-title":"J Clin Psychiatry"},{"key":"134_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/gps.2355","volume":"25","author":"JT Olin","year":"2010","unstructured":"Olin JT, Bhatnagar V, Reyes P, Koumaras B, Meng X, Brannan S: Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32). Int J Geriatr Psychiatry. 2010, 25: 419-426. 10.1002\/gps.2355.","journal-title":"Int J Geriatr Psychiatry"},{"key":"134_CR41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/11591860-000000000-00000","volume":"28","author":"L Patel","year":"2011","unstructured":"Patel L, Grossberg GT: Combination therapy for Alzheimer's disease. Drugs Aging. 2011, 28: 539-546. 10.2165\/11591860-000000000-00000.","journal-title":"Drugs Aging"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/alzrt160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/alzrt160\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/alzrt160.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T06:28:52Z","timestamp":1728368932000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/alzrt160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,1,21]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,2]]}},"alternative-id":["134"],"URL":"https:\/\/doi.org\/10.1186\/alzrt160","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,1,21]]},"assertion":[{"value":"10 September 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"6"}}